Abbott Laboratories $ABT Shares Sold by Westpac Banking Corp

Westpac Banking Corp decreased its stake in shares of Abbott Laboratories (NYSE:ABT) by 36.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,029 shares of the healthcare product maker’s stock after selling 7,990 shares during the period. Westpac Banking Corp’s holdings in Abbott Laboratories were worth $1,758,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories during the fourth quarter worth approximately $25,000. Harbor Capital Advisors Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth $27,000. Bridge Generations Wealth Management LLC acquired a new stake in shares of Abbott Laboratories in the third quarter worth $33,000. Leonteq Securities AG acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth $35,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT opened at $87.15 on Thursday. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06. The company has a 50-day moving average of $93.34 and a two-hundred day moving average of $109.72. The stock has a market cap of $151.80 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 1.45 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Insider Buying and Selling

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ? increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Sanford C. Bernstein reduced their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Barclays lowered their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. Evercore lowered their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Wells Fargo & Company lowered their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Finally, Jefferies Financial Group lowered their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $119.09.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.